These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 32517181)

  • 21. Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer.
    Kendrick ZW; Firpo MA; Repko RC; Scaife CL; Adler DG; Boucher KM; Mulvihill SJ
    HPB (Oxford); 2014 Jul; 16(7):670-6. PubMed ID: 24308545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial.
    Beatty GL; O'Hara MH; Lacey SF; Torigian DA; Nazimuddin F; Chen F; Kulikovskaya IM; Soulen MC; McGarvey M; Nelson AM; Gladney WL; Levine BL; Melenhorst JJ; Plesa G; June CH
    Gastroenterology; 2018 Jul; 155(1):29-32. PubMed ID: 29567081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy for pancreatic ductal adenocarcinoma.
    Carpenter E; Nelson S; Bednar F; Cho C; Nathan H; Sahai V; di Magliano MP; Frankel TL
    J Surg Oncol; 2021 Mar; 123(3):751-759. PubMed ID: 33595893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
    Hilmi M; Bartholin L; Neuzillet C
    World J Gastroenterol; 2018 May; 24(20):2137-2151. PubMed ID: 29853732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CKAP4, a DKK1 Receptor, Is a Biomarker in Exosomes Derived from Pancreatic Cancer and a Molecular Target for Therapy.
    Kimura H; Yamamoto H; Harada T; Fumoto K; Osugi Y; Sada R; Maehara N; Hikita H; Mori S; Eguchi H; Ikawa M; Takehara T; Kikuchi A
    Clin Cancer Res; 2019 Mar; 25(6):1936-1947. PubMed ID: 30610103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.
    Le DT; Wang-Gillam A; Picozzi V; Greten TF; Crocenzi T; Springett G; Morse M; Zeh H; Cohen D; Fine RL; Onners B; Uram JN; Laheru DA; Lutz ER; Solt S; Murphy AL; Skoble J; Lemmens E; Grous J; Dubensky T; Brockstedt DG; Jaffee EM
    J Clin Oncol; 2015 Apr; 33(12):1325-33. PubMed ID: 25584002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNAs: novel diagnostic and therapeutic tools for pancreatic ductal adenocarcinoma?
    Mardin WA; Mees ST
    Ann Surg Oncol; 2009 Nov; 16(11):3183-9. PubMed ID: 19636633
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of ILK and ERP29 expressions in benign and malignant pancreatic lesions and their clinicopathological significances in pancreatic ductal adenocarcinomas.
    Zhang K; Yao H; Yang Z; Li D; Yang L; Zou Q; Yuan Y; Miao X
    Clin Transl Oncol; 2016 Apr; 18(4):352-9. PubMed ID: 26887611
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pancreatic metastases of renal clear cell carcinoma: a clinicopathological study of 11 cases with special emphasis on the usefulness of PAX2 and mesothelin for the distinction from primary ductal adenocarcinoma of the pancreas.
    Gnemmi V; Leroy X; Triboulet JP; Pruvot FR; Villers A; Leteurtre E; Buob D
    Anal Quant Cytopathol Histpathol; 2013 Jun; 35(3):157-62. PubMed ID: 24344503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Accurate discrimination of pancreatic ductal adenocarcinoma and chronic pancreatitis using multimarker expression data and samples obtained by minimally invasive fine needle aspiration.
    Chen Y; Zheng B; Robbins DH; Lewin DN; Mikhitarian K; Graham A; Rumpp L; Glenn T; Gillanders WE; Cole DJ; Lu X; Hoffman BJ; Mitas M
    Int J Cancer; 2007 Apr; 120(7):1511-7. PubMed ID: 17192896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC).
    Chen H; Yang G; Xiao J; Zheng L; You L; Zhang T
    Cancer Lett; 2020 Oct; 490():12-19. PubMed ID: 32590021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches.
    Orth M; Metzger P; Gerum S; Mayerle J; Schneider G; Belka C; Schnurr M; Lauber K
    Radiat Oncol; 2019 Aug; 14(1):141. PubMed ID: 31395068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope.
    Liu XF; Onda M; Schlomer J; Bassel L; Kozlov S; Tai CH; Zhou Q; Liu W; Tsao HE; Hassan R; Ho M; Pastan I
    Proc Natl Acad Sci U S A; 2024 Jan; 121(4):e2317283121. PubMed ID: 38227666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.
    Nichetti F; Marra A; Corti F; Guidi A; Raimondi A; Prinzi N; de Braud F; Pusceddu S
    Target Oncol; 2018 Jun; 13(3):333-351. PubMed ID: 29656320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New Diagnostic and Therapeutic Aspects of Pancreatic Ductal Adenocarcinoma.
    Mangge H; Niedrist T; Renner W; Lyer S; Alexiou C; Haybaeck J
    Curr Med Chem; 2017; 24(28):3012-3024. PubMed ID: 28494747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The correlation between gut and intra-tumor microbiota and PDAC: Etiology, diagnostics and therapeutics.
    Qian J; Zhang X; Wei B; Tang Z; Zhang B
    Biochim Biophys Acta Rev Cancer; 2023 Sep; 1878(5):188943. PubMed ID: 37355177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.
    Sun J; Bi F; Yang Y; Zhang Y; Jin A; Li J; Lin Z
    Oncol Rep; 2017 Feb; 37(2):857-864. PubMed ID: 27959420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of mesothelin as a tumor-associated antigen in cervical squamous cell carcinoma.
    He Y; Zhao H; Li XM; Yin CH; Wu YM
    Gene; 2019 Mar; 690():30-37. PubMed ID: 30583024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Leukemia Inhibitory Factor: A Potential Biomarker and Therapeutic Target in Pancreatic Cancer.
    Wrona E; Potemski P; Sclafani F; Borowiec M
    Arch Immunol Ther Exp (Warsz); 2021 Feb; 69(1):2. PubMed ID: 33630157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.